abbott.mediaroom

Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System

SonicForce is an investigational coronary intravascular lithotripsy (IVL) system that uses acoustic pressure waves, similar to those used to break up kidney stones, to crack calcium in ...
abbott.mediaroom

Abbott launches whole-genome sequencing Oncodetect® molecular residual disease (MRD) test to detect traces of cancer during and after treatment

Powered by whole-genome sequencing and MAESTRO* technology, the next-generation Oncodetect test takes a distinct approach to MRD, tracking up to 5,000 patient-specific variants with a limit ...
abbott.mediaroom

Abbott initiates pivotal trial for Cephea™ device, an innovative treatment for mitral heart valve disease

CROWN-MV trial will evaluate the safety and effectiveness of investigational Cephea mitral valve replacement device Abbott's Cephea is designed to provide a new, minimally invasive option ...
abbott.mediaroom

Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer

Beta-CORRECT study shows a 10.6-fold higher risk of recurrence, reinforcing the prognostic value of molecular residual disease (MRD) testing1 Building on its leadership in colorectal ...
abbott.mediaroom

Abbott's Cologuard Plus® receives CE Mark for colorectal cancer screening in Europe

Cologuard Plus is a noninvasive, stool-based DNA screening test designed to detect both colorectal cancer and advanced precancerous lesions In the pivotal BLUE-C study, Cologuard Plus ...
abbott.mediaroom

Abbott Receives FDA Approval for the FreeStyle Libre Pro™ System, a Revolutionary Diabetes Sensing Technology for Healthcare Professionals to Use with Their Patients

ABBOTT PARK, Ill., Sept. 28, 2016 — Abbott today announced that the U.S. Food and Drug Administration (FDA) has approved the company's FreeStyle Libre Pro system, a revolutionary continuous glucose ...
abbott.mediaroom

Abbott acquisition of Exact Sciences set to close on March 23, 2026

Announcement follows receipt of all regulatory clearances necessary for closing Transaction enables Abbott to enter and lead in fast-growing cancer screening and diagnostics segments, serving millions ...
abbott.mediaroom

Abbott Reports Second-Quarter 2025 Results

The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information." Reflects the net tax benefit associated with the ...
abbott.mediaroom

Abbott Reports Third-Quarter 2025 Results and Reaffirms Full-Year Guidance

The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information." Restructuring and cost reduction initiative ...
abbott.mediaroom

Abbott Reports Fourth-Quarter and Full-Year 2023 Results; Issues 2024 Financial Outlook

The table above provides additional details regarding the specified items described on tables titled "Non-GAAP Reconciliation of Financial Information." a) Acquisition-related expenses include ...
abbott.mediaroom

Abbott to Acquire Alere, Becoming Leader in Point of Care Testing and Significantly Advancing Global Diagnostics Presence

ABBOTT PARK, Ill. and WALTHAM, Mass., Feb. 1, 2016 /PRNewswire/ -- Abbott (NYSE: ABT) and Alere Inc. (NYSE: ALR) announced today a definitive agreement for Abbott to acquire Alere, significantly ...
abbott.mediaroom

Abbott Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Financial Outlook

The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information." Restructuring and cost reduction initiative ...